PURPOSE: To determine the effect of antibodies against recombinant human acid α-glucosidase (rhGAA) on treatment efficacy and safety, and to test whether the GAA genotype is involved in antibody formation. METHODS: We used enzyme-linked immunosorbent assay (ELISA) to determine anti-rhGAA antibody titers at baseline and at 6, 12, and 36 months of rhGAA treatment. We measured the capacity of antibodies to neutralize rhGAA enzymatic activity or cellular uptake and the effects on infusion-associated reactions (IARs), muscle strength, and pulmonary function. RESULTS: Of 73 patients, 45 developed antibodies. Maximal titers were high (≥1:31,250) in 22% of patients, intermediate (1:1,250-1:31,250) in 40%, and none or low (0-1:1,250) in 38%. The common IVS1/delex18 GAA genotype was absent only in the high-titer group. The height of the titer positively correlated with the occurrence and number of IARs (P ≤ 0.001). On the group level, antibody titers did not correlate with treatment efficacy. Eight patients (11%) developed very high maximal titers (≥156,250), but only one patient showed high sustained neutralizing antibodies that probably interfered with treatment efficacy. CONCLUSIONS: In adults with Pompe disease, antibody formation does not interfere with rhGAA efficacy in the majority of patients, is associated with IARs, and may be attenuated by the IVS1/delex18 GAA genotype.Genet Med 19 1, 90-97.
PURPOSE: To determine the effect of antibodies against recombinant human acid α-glucosidase (rhGAA) on treatment efficacy and safety, and to test whether the GAA genotype is involved in antibody formation. METHODS: We used enzyme-linked immunosorbent assay (ELISA) to determine anti-rhGAA antibody titers at baseline and at 6, 12, and 36 months of rhGAA treatment. We measured the capacity of antibodies to neutralize rhGAA enzymatic activity or cellular uptake and the effects on infusion-associated reactions (IARs), muscle strength, and pulmonary function. RESULTS: Of 73 patients, 45 developed antibodies. Maximal titers were high (≥1:31,250) in 22% of patients, intermediate (1:1,250-1:31,250) in 40%, and none or low (0-1:1,250) in 38%. The common IVS1/delex18 GAA genotype was absent only in the high-titer group. The height of the titer positively correlated with the occurrence and number of IARs (P ≤ 0.001). On the group level, antibody titers did not correlate with treatment efficacy. Eight patients (11%) developed very high maximal titers (≥156,250), but only one patient showed high sustained neutralizing antibodies that probably interfered with treatment efficacy. CONCLUSIONS: In adults with Pompe disease, antibody formation does not interfere with rhGAA efficacy in the majority of patients, is associated with IARs, and may be attenuated by the IVS1/delex18 GAA genotype.Genet Med 19 1, 90-97.
Authors: M A Kroos; R J Pomponio; M L Hagemans; J L M Keulemans; M Phipps; M DeRiso; R E Palmer; M G E M Ausems; N A M E Van der Beek; O P Van Diggelen; D J J Halley; A T Van der Ploeg; A J J Reuser Journal: Neurology Date: 2007-01-09 Impact factor: 9.910
Authors: William R Wilcox; Gabor E Linthorst; Dominique P Germain; Ulla Feldt-Rasmussen; Stephen Waldek; Susan M Richards; Dana Beitner-Johnson; Marta Cizmarik; J Alexander Cole; Wytske Kingma; David G Warnock Journal: Mol Genet Metab Date: 2011-12-14 Impact factor: 4.797
Authors: Juna M de Vries; Nadine A M E van der Beek; Marian A Kroos; Lale Ozkan; Pieter A van Doorn; Susan M Richards; Crystal C C Sung; Jan-Dietert C Brugma; Adrienne A M Zandbergen; Ans T van der Ploeg; Arnold J J Reuser Journal: Mol Genet Metab Date: 2010-08-14 Impact factor: 4.797
Authors: Melissa E Elder; Sushrusha Nayak; Shelley W Collins; Lee Ann Lawson; Jeffry S Kelley; Roland W Herzog; Renee F Modica; Judy Lew; Robert M Lawrence; Barry J Byrne Journal: J Pediatr Date: 2013-04-16 Impact factor: 4.406
Authors: Lorne A Clarke; J Edmond Wraith; Michael Beck; Edwin H Kolodny; Gregory M Pastores; Joseph Muenzer; David M Rapoport; Kenneth I Berger; Marisa Sidman; Emil D Kakkis; Gerald F Cox Journal: Pediatrics Date: 2009-01 Impact factor: 7.124
Authors: Suhrad G Banugaria; Sean N Prater; Yiu-Ki Ng; Joyce A Kobori; Richard S Finkel; Roger L Ladda; Yuan-Tsong Chen; Amy S Rosenberg; Priya S Kishnani Journal: Genet Med Date: 2011-08 Impact factor: 8.822
Authors: Carin M van Gelder; Marianne Hoogeveen-Westerveld; Marian A Kroos; Iris Plug; Ans T van der Ploeg; Arnold J J Reuser Journal: J Inherit Metab Dis Date: 2014-04-09 Impact factor: 4.982
Authors: Marion M Brands; Marianne Hoogeveen-Westerveld; Marian A Kroos; Willemieke Nobel; George J Ruijter; Lale Özkan; Iris Plug; Daniel Grinberg; Lluïsa Vilageliu; Dicky J Halley; Ans T van der Ploeg; Arnold J Reuser Journal: Orphanet J Rare Dis Date: 2013-04-04 Impact factor: 4.123
Authors: Su Xu; Yi Lun; Michelle Frascella; Anadina Garcia; Rebecca Soska; Anju Nair; Abdul S Ponery; Adriane Schilling; Jessie Feng; Steven Tuske; Maria Cecilia Della Valle; José A Martina; Evelyn Ralston; Russell Gotschall; Kenneth J Valenzano; Rosa Puertollano; Hung V Do; Nina Raben; Richie Khanna Journal: JCI Insight Date: 2019-03-07
Authors: Juna M de Vries; Esther Kuperus; Marianne Hoogeveen-Westerveld; Marian A Kroos; Stephan C A Wens; Merel Stok; Nadine A M E van der Beek; Michelle E Kruijshaar; Dimitris Rizopoulos; Pieter A van Doorn; Ans T van der Ploeg; W W M Pim Pijnappel Journal: Genet Med Date: 2017-06-29 Impact factor: 8.822
Authors: Esther Kuperus; Jan C van der Meijden; Stijn L M In 't Groen; Marian A Kroos; Marianne Hoogeveen-Westerveld; Dimitris Rizopoulos; Monica Yasmin Nino Martinez; Michelle E Kruijshaar; Pieter A van Doorn; Nadine A M E van der Beek; Ans T van der Ploeg; W W M Pim Pijnappel Journal: PLoS One Date: 2018-12-07 Impact factor: 3.240
Authors: E Poelman; M Hoogeveen-Westerveld; J M P van den Hout; R G M Bredius; A C Lankester; G J A Driessen; S S M Kamphuis; W W M Pijnappel; A T van der Ploeg Journal: Orphanet J Rare Dis Date: 2019-03-22 Impact factor: 4.123
Authors: Jan C van der Meijden; Michelle E Kruijshaar; Laurike Harlaar; Dimitris Rizopoulos; Nadine A M E van der Beek; Ans T van der Ploeg Journal: J Inherit Metab Dis Date: 2018-03-19 Impact factor: 4.982